ArticleClinical drug investigation2020

An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.

Arielle G Bensimon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.